All In Biotech

Drug Trial Radar · NCT06989957

Psilocybin and Methylenedioxymethamphetamine (MDMA) for Post-traumatic Stress Disorder (PTSD)

Psilocybin and MDMA for Post-traumatic Stress Disorder (PTSD)

Last checked: Nov 20, 2026Latest source record: Sep 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

40

Planned (sponsor's estimate)

Start

Sep 17, 2025

Primary completion

Aug 2028

Study completion Aug 2029

Sponsor

Lead sponsor
Johns Hopkins UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Gracias Family Foundation
First posted
May 25, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 21 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the safety and effectiveness of co-administered MDMA and psilocybin in military Veterans with a diagnosis of Posttraumatic Stress Disorder (PTSD). To apply or learn more, please view our website: https://hopkinspsychedelic.org/pamvet

Conditions

  • Posttraumatic Stress Disorder

Interventions

  • PsilocybinDrug

    Experimental Psilocybin (exact dosages not disclosed)

  • PsilocybinDrug

    Comparator Psilocybin (exact dosages not disclosed)

  • MDMADrug

    Experimental MDMA (exact dosages not disclosed)

  • MDMADrug

    Comparator MDMA (exact dosages not disclosed)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Adverse EventsTime frame: 30 weeks
  2. The Columbia Suicide Severity Rating Scale (C-SSRS)Time frame: 33 weeks
  3. Clinician-Administered PTSD Scale for Diagnostic and Statistical Manual-5 (CAPS-5)Time frame: 33 weeks
  4. PTSD Checklist (PCL-5)Time frame: 33 weeks
  5. World Health Organization Quality of Life- Brief version (WHOQOL-BREF)Time frame: 33 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Johns Hopkins Center for Psychedelic and Consciousness Research

    Baltimore, Maryland · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.